Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

Real-life treatment of patients with cholinergic urticaria in Germanspeaking countries

Filename 367. Mellerowicz et al., engl, Real-life treatment chol. urt., JDDG 2019.pdf
Filesize 391.36 KB
Version o.367
Date added June 5, 2019
Downloaded 4 times
Category Original Work
Tags cholinergic urticaria
Authors Mellerowicz, E., Weller, K., Zuberbier, T., Maurer, M., and Altrichter, S.
Citation Mellerowicz, E., Weller, K., Zuberbier, T., Maurer, M., and Altrichter, S.: Real life treatment of patients with cholinergic urticaria in German speaking countries. J. Dtsch. Dermatol. Ges. 2019: 17; 1141-1147.
Corresponding authors Maurer, M.
DocNum o.367
DocType PDF
Edition; Page 17; 1141-1147
IF 3.66
Publisher J. Dtsch. Dermatol. Ges.
ReleaseDate 2019

Background: Cholinergic urticaria (CholU) is a frequent type of chronic inducible urticaria. Symptomatic treatment with second-generation antihistamines (sgAH) is recommended by current guidelines as first-line therapy, but little is known about how patients with CholU are treated in real life and how they respond to treatment.

Aim: To assess real-life treatment of CholU in German-speaking countries.

Methods: Patients with CholU (n = 111) took part in an online survey study that assessed their treatments and their treatment responses.

Results: Virtually all patients (97 %) had used antihistamines, 87 % of them sgAH; 23 % had also taken first-generation antihistamines (fgAH). The proportion of patients who benefited from standard-dosed antihistamine treatment was low (sgAH: 32 % vs. fgAH: 16 %), and side effects of sgAH and fgAH were comparable. Updosing of antihistamines had been tried by 66 patients (59 %) (most commonly [98 %, n = 65] with sgAH) and resulted in marginally better responses (sgAH: 38 % vs. fgAH: 32 %). Only very few patients had used other treatments, mostly corticosteroids (30 %) and omalizumab (5 %).

Conclusions: SgAH were commonly used, but insufficient in about two thirds of CholU patients. Accordingly, improved use of third-line and fourth-line treatment options and development of better therapies for patients with CholU are needed.

 

(Last update: 12.2023)

Number of original publications in peer-reviewed journals:580
Number of reviews in peer-reviewed journals:210
Number of publications (original work and reviews) in peer-reviewed journals:790
Cumulative IF for original publications in peer-reviewed journals:4196.39
Cumulative IF for reviews in peer-reviewed journals:1409.32
Cumulative IF of publications (original work & reviews) in peer-reviewed journals:5605.71
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023)36836

Download-Information

To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.